The Meningococcal B Vaccine Study (Visits Only)

This study is evaluating a new vaccine for the prevention of Neisseria meningitidis (meningococcal disease) is an infection disease that is spread from person to person through regular close contact via respiratory droplets. Meningococcal disease can cause IMD, a rare but serious disease that most commonly presents as meningitis, inflammation of the spinal fluid and the tissues that surround the brain.

Vaccination is an essential method of preventing infectious diseases, such as Meningococcal disease. Vaccines typically contain fragments of bacterial or viral proteins that are made in the lab. They work by training the body’s immune system to recognise these bacterial or viral proteins as harmful.

The purpose of this research study is to evaluate the safety of and the body’s immune response to multiple single vaccine doses in healthy men and women, while comparing the study vaccine to an existing approved meningococcal vaccine in Australia.